Molecular profiling reveals potential targets in cholangiocarcinoma

Figure 5 Targeting cell cycle and Notch pathways inhibited cell growth of human cholangiocarcinoma cell lines. Growth curves of three cholangiocarcinoma cell lines with different genetic background, e.g., HuCCT1 (KRAS and P53 mutations), RBE (IDH1 mutation), and H1, treated with cell cycle and Notch inhibitors, respectively. For targeting cell cycle pathways, (A) D1-dependent CDK4 inhibitor Arcyriaflavin a, (B) pan-CDK inhibitor Flavopiridol, (C) selected CDK inhibitor Roscovitine were utilized, and (D) the γ-secretase inhibitor (DAPT) was used against Notch pathway. Absorbance at OD570 nm and 650 nm analyzed by MTT, and then normalized to vehicle control (0.1% DMSO or the corresponding medium; n = 6 wells/dose point). The relative cell proliferation rates were calculated as OD570 - OD650. ^aP < 0.05, ^bP < 0.01, and ^cP < 0.001 when compared with the vehicle control at day 7.